CellCentric Ltd

CellCentric Ltd, based in the UK, is focused on developing innovative pharmaceutical therapies, particularly targeting cancer treatment through advanced molecular inhibitors. Founded in 2003 and headquartered in Cambridge, UK, CellCentric Ltd concentrates on the development of pharmaceutical therapies, specifically their lead product, inobrodib. The company has engaged in 12 deals, culminating in a Series C funding round in May 2025, where they raised USD 120. 00 mn from notable investors including Avego Healthcare Capital and RA Capital.

The company is led by CEO Will West, who has a history of involvement in similar ventures, although specific prior companies are not detailed here. CellCentric specializes in innovative pharmaceutical therapies, with its core product, inobrodib, a first-in-class small molecule inhibitor. This drug selectively targets the p300/CBP proteins to disrupt cancer cell growth, particularly in treating multiple myeloma. Inobrodib is undergoing clinical trials and is designed for oral administration, aiming to ease the treatment process for patients.

Their clientele consists mainly of healthcare providers and oncology specialists across North America, Europe, and parts of Asia, who are seeking new cancer therapy options. CellCentric's revenue model involves partnerships with research institutions and pharmaceutical companies for the development and commercialization of inobrodib. The revenue anticipated from licensing agreements and future sales hinges on the regulatory approval and market entry of inobrodib. In 2011, the reported revenue was USD 0 mn, and for the most recent fiscal year, EBITDA was also reported at USD 0.

CellCentric aims to leverage its recent Series C funding, which raised USD 120. 00 mn in May 2025, to advance the clinical stages of inobrodib for treating multiple myeloma. The company is also exploring opportunities to expand into additional markets, with particular focus on reaching more regions in Asia and Europe by 2026. The funding will predominantly support further clinical trials and regulatory compliance for inobrodib, setting the stage for its eventual market introduction.

In May 2026, CellCentric Ltd raised USD 220 million in series D funding led by new investor Venrock Healthcare Capital Partners, with participation from other new investors Fidelity Investments, HBM Partners, and Sofinnova Partners. Returning investors Avego, BrightEdge Ventures, Forbion, Pfizer Inc. , RA Capital Management, and other unspecified investors also participated in the round. The company will use the May 2026 funding to support registration trials, continue development of its drug candidate, and advance studies across multiple treatment settings.